Research programme: FF2 - Nuada

Drug Profile

Research programme: FF2 - Nuada

Alternative Names: FF2 research programme - Nuada; Muscarinic M3 receptor antagonists research programme - Nuada; Research programme: muscarinic M3 receptor antagonists - Nuada

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator Nuada Pharmaceuticals
  • Class
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Urinary incontinence

Most Recent Events

  • 23 Mar 2004 Preclinical trials in Urinary incontinence in USA (unspecified route)
  • 23 Mar 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
  • 23 Mar 2004 Nuada's FF2 programme is available for partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top